Using an inducible transgenic mouse model, Lopez et al., developed a model that phenocopied the human AML CBFA2T3-GLIS2 disease: they demonstrated striking differences in latency, phenotype, and molecular wiring, depending on the ontogenic stage at which the driver fusion oncogene was activated [5]. This evidence concerns the gene GLIS2 and acute myeloid leukemia.